Replies to post #161932 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

This release says...
"The Thesis
Biogen’s fate is seen to hinge on its Alzheimer’s therapy, with the odds of success being better than 50-50, Matteis said in a note.

“From a sentiment perspective, we think the stock — in a positive or negative Alzheimer's scenario — could overshoot its fundamental value,” the analyst said.

Stifel read Phase 1b aducanumab data with more forgiveness than investors did given the treatment’s differentiated profile.

“The hardest thing to get comfort with is that the effect size — even if Aducanumab does work — is small, so, even if the drug does work, there are still exogenous variables that place the trial at risk."
Ya Think?
https://finance.yahoo.com/news/stifel-buys-back-biogen-sees-182610132.html